Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
ANRO
$19.5617
$
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company that engages in the psychiatry drug development business. The company develops ALTO-100 for the treatment of patients with major depressive disorder (MDD) and post-traumatic stress disorder; ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties to treat patients with MDD; and ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor for the treatment of cognitive impairment associated with schizophrenia. It also develops ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist to treat patients with MDD and higher levels of anhedonia, and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor for the treatment of MDD. In addition, the company develops novel pharmacodynamically synergistic combinations and an AI-enabled biomarker platform that combine sources of information on patients brain activity and behavior to identify patients to respond to novel product candidates. Alto Neuroscience, Inc. was incorporated in 2019 and is based in Los Altos, California.
Next Earnings
2026-02-25
Beta
2.851
Average Volume
Market Cap
Last Dividend
CIK
0001999480
ISIN
US02157Q1094
CUSIP
02157Q109
CEO
Amit Etkin
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
76
IPO Date
2024-02-02
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| Alto Neuroscience Announces Participation in Upcoming Investor Conferences | MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Company's management team will participate in the following upcoming investor conferences: TD Cowen 46th Annual Healthcare Conference, March 2-5, 2026 Format: Fireside chat and one-on-one meetings Presentation Date & Time: March 3, 2026, 1:50. | Business Wire | 2026-02-23 08:33:00 |
| Alto Neuroscience Announces Completion of Enrollment in Phase 2 Proof-of-Concept Study of ALTO-101 in Cognitive Impairment Associated with Schizophrenia | MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the completion of patient enrollment in its Phase 2 proof-of-concept clinical trial evaluating ALTO-101, a novel, transdermal phosphodiesterase-4 (PDE4) inhibitor, for the treatment of cognitive impairment associated with schizophrenia (CIAS). Topline data from the. | Business Wire | 2026-02-13 08:04:00 |
| Alto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment | MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #Neuroplasticity--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the publication of a review, "Brain Neuroplasticity Mechanisms in Psychiatric Illnesses and in the Development of Novel Treatments," in the American Journal of Psychiatry. The review was co-authored by members of Alto Neuroscience's leadership team, Patricio O'Donn. | Business Wire | 2026-02-03 08:27:00 |
| Alto Neuroscience Strengthens Intellectual Property Portfolio with Issuance of New Method-of-Treatment Patent for ALTO-207 in Depression | MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the issuance of U.S. Patent Number 12,521,374 covering methods of treating depression with ALTO-207, a novel combination of pramipexole and ondansetron. The patent protects a key aspect of ALTO-207 – the use of ondansetron to mitigate pramipexole-related side effec. | Business Wire | 2026-01-14 07:27:00 |
| Alto Neuroscience Presents New Data at the 64th Annual Meeting of the American College of Neuropsychopharmacology | MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #ACNP--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced multiple presentations highlighting new data and analyses supporting the Company's development programs at the 64th annual meeting of the American College of Neuropsychopharmacology (ACNP) held January 12-15, 2026. “We are pleased to have the opportunity to showcas. | Business Wire | 2026-01-13 08:00:00 |
| Alto Neuroscience (NYSE:ANRO) Trading Down 6% – Here’s Why | Shares of Alto Neuroscience, Inc. (NYSE: ANRO - Get Free Report) were down 6% during mid-day trading on Friday. The company traded as low as $16.90 and last traded at $16.74. Approximately 59,931 shares changed hands during trading, a decline of 86% from the average daily volume of 425,848 shares. The stock had previously closed | Defense World | 2026-01-04 05:46:53 |
| Alto Neuroscience, Inc. $ANRO Shares Sold by AWM Investment Company Inc. | AWM Investment Company Inc. trimmed its stake in shares of Alto Neuroscience, Inc. (NYSE: ANRO) by 68.9% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 280,483 shares of the company's stock after selling 621,501 shares during the | Defense World | 2025-12-13 03:50:50 |
| Alto Neuroscience Announces New Employee Inducement Grants Under NYSE Rule 303A.08 | MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that on December 2, 2025, the Compensation and Management Development Committee of Alto's Board of Directors granted a new employee an option to purchase 150,000 shares of Alto's common stock. The stock option was granted under Alto's 2025 Inducement Plan as a mate. | Business Wire | 2025-12-03 16:05:00 |
| Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Alto Neuroscience, Inc. (ANRO), Atkore Inc. (ATKR), Dow Inc. (DOW), and Fly-E Group, Inc. (FLYE) | SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of current, long-term shareholders of Alto Neuroscience, Inc. (NYSE: ANRO), Atkore Inc. (NYSE: ATKR), Dow Inc. (NYSE: DOW), and Fly-E Group, Inc. | Globe News Wire | 2025-12-01 17:42:00 |
| Alto Neuroscience: 4 Shots At Success In CNS Diseases In 2026 | Alto Neuroscience, Inc. is positioned as a precision medicine innovator in CNS disorders, with major clinical readouts expected in 2026. ANRO's pipeline targets high unmet needs in depression, bipolar disorder, and schizophrenia, leveraging biomarkers to optimize drug efficacy and patient selection. The company has a strong cash runway into 2028, experienced leadership, and potential for significant upside if upcoming trials are successful. | Seeking Alpha | 2025-11-28 12:38:04 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| SC 13G/A | 2026-02-18 | 2026-02-18 | View Filing |
| SC 13G/A | 2026-02-17 | 2026-02-17 | View Filing |
| SC 13G/A | 2026-02-17 | 2026-02-17 | View Filing |
| SC 13G/A | 2026-02-17 | 2026-02-17 | View Filing |
| SC 13G/A | 2026-02-17 | 2026-02-17 | View Filing |
| SC 13G | 2026-02-17 | 2026-02-17 | View Filing |
| SC 13G/A | 2026-02-17 | 2026-02-17 | View Filing |
| 4 | 2026-02-13 | 2026-02-13 | View Filing |
| 4 | 2026-02-13 | 2026-02-13 | View Filing |
| 4 | 2026-02-13 | 2026-02-13 | View Filing |
| 4 | 2026-02-13 | 2026-02-13 | View Filing |
| 4 | 2026-01-06 | 2026-01-06 | View Filing |
| 4 | 2026-01-06 | 2026-01-06 | View Filing |
| 4 | 2026-01-06 | 2026-01-06 | View Filing |
| 4 | 2026-01-06 | 2026-01-06 | View Filing |
| EFFECT | 2025-12-10 | 2025-12-11 | View Filing |
| S-3 | 2025-11-28 | 2025-11-26 | View Filing |
| 10-Q | 2025-11-12 | 2025-11-12 | View Filing |
| 8-K | 2025-11-12 | 2025-11-12 | View Filing |
| D | 2025-10-27 | 2025-10-27 | View Filing |
| SC 13G | 2025-10-27 | 2025-10-27 | View Filing |
| 8-K | 2025-10-20 | 2025-10-20 | View Filing |
| SC 13G | 2025-10-10 | 2025-10-10 | View Filing |
| SC 13G/A | 2025-08-14 | 2025-08-14 | View Filing |
| 4 | 2025-08-14 | 2025-08-14 | View Filing |
| 3 | 2025-08-14 | 2025-08-14 | View Filing |
| 10-Q | 2025-08-13 | 2025-08-13 | View Filing |
| 8-K | 2025-08-13 | 2025-08-13 | View Filing |
| SC 13G/A | 2025-07-16 | 2025-07-16 | View Filing |
| 4 | 2025-07-08 | 2025-07-08 | View Filing |
| 4 | 2025-07-08 | 2025-07-08 | View Filing |
| 4 | 2025-07-08 | 2025-07-08 | View Filing |
| 4 | 2025-07-08 | 2025-07-08 | View Filing |
| 8-K | 2025-07-08 | 2025-07-08 | View Filing |
| 8-K | 2025-06-26 | 2025-06-26 | View Filing |
| 8-K | 2025-06-03 | 2025-06-03 | View Filing |
| SC 13G/A | 2025-05-15 | 2025-05-15 | View Filing |
| 4 | 2025-05-15 | 2025-05-15 | View Filing |
| 4 | 2025-05-15 | 2025-05-15 | View Filing |
| 4 | 2025-05-15 | 2025-05-15 | View Filing |
| 4 | 2025-05-15 | 2025-05-15 | View Filing |
| SC 13G | 2025-05-15 | 2025-05-15 | View Filing |
| SC 13G | 2025-05-15 | 2025-05-15 | View Filing |
| 10-Q | 2025-05-14 | 2025-05-14 | View Filing |
| 8-K | 2025-05-14 | 2025-05-14 | View Filing |
| DEFR14A | 2025-05-09 | 2025-05-09 | View Filing |
| ARS | 2025-04-01 | 2025-04-01 | View Filing |
| DEFA14A | 2025-04-01 | 2025-04-01 | View Filing |
| DEF 14A | 2025-04-01 | 2025-04-01 | View Filing |
| S-8 | 2025-03-20 | 2025-03-20 | View Filing |
| 10-K | 2025-03-20 | 2025-03-20 | View Filing |
| 8-K | 2025-03-20 | 2025-03-20 | View Filing |
| SC 13G/A | 2025-02-14 | 2025-02-14 | View Filing |
| SC 13G/A | 2025-02-14 | 2025-02-14 | View Filing |
| SC 13G/A | 2025-02-12 | 2025-02-12 | View Filing |
| 8-K | 2025-02-12 | 2025-02-12 | View Filing |
| EFFECT | 2025-02-12 | 2025-02-12 | View Filing |
| 4 | 2025-02-07 | 2025-02-07 | View Filing |
| 4 | 2025-02-07 | 2025-02-07 | View Filing |
| 4 | 2025-02-07 | 2025-02-07 | View Filing |
| 4 | 2025-02-07 | 2025-02-07 | View Filing |
| 8-K | 2025-02-03 | 2025-02-03 | View Filing |
| S-3 | 2025-02-03 | 2025-02-03 | View Filing |
| 8-K | 2025-01-16 | 2025-01-16 | View Filing |
| 4 | 2025-01-06 | 2025-01-06 | View Filing |
| 4 | 2025-01-06 | 2025-01-06 | View Filing |
| 4 | 2025-01-06 | 2025-01-06 | View Filing |
| SC 13G/A | 2024-11-14 | 2024-11-14 | View Filing |
| SC 13G | 2024-11-14 | 2024-11-14 | View Filing |
| 10-Q | 2024-11-12 | 2024-11-12 | View Filing |
| 8-K | 2024-11-12 | 2024-11-12 | View Filing |
| SC 13G | 2024-11-12 | 2024-11-12 | View Filing |
| SC 13G | 2024-11-08 | 2024-11-08 | View Filing |
| 8-K | 2024-10-22 | 2024-10-22 | View Filing |
| SC 13G | 2024-10-21 | 2024-10-21 | View Filing |
| 10-Q | 2024-08-13 | 2024-08-13 | View Filing |
| 8-K | 2024-08-13 | 2024-08-13 | View Filing |
| 8-K | 2024-07-29 | 2024-07-29 | View Filing |
| 4 | 2024-07-11 | 2024-07-11 | View Filing |
| 4 | 2024-05-22 | 2024-05-22 | View Filing |
| 3 | 2024-05-22 | 2024-05-22 | View Filing |
| 8-K | 2024-05-21 | 2024-05-21 | View Filing |
| 10-Q | 2024-05-14 | 2024-05-14 | View Filing |
| 8-K | 2024-05-14 | 2024-05-14 | View Filing |
| 4 | 2024-04-01 | 2024-04-01 | View Filing |
| SC 13G | 2024-03-29 | 2024-03-29 | View Filing |
| 10-K | 2024-03-21 | 2024-03-21 | View Filing |
| 8-K | 2024-03-21 | 2024-03-21 | View Filing |
| 4 | 2024-03-12 | 2024-03-12 | View Filing |
| 3 | 2024-03-12 | 2024-03-12 | View Filing |
| 8-K | 2024-03-11 | 2024-03-11 | View Filing |
| 4 | 2024-03-06 | 2024-03-06 | View Filing |
| 4 | 2024-03-05 | 2024-03-05 | View Filing |
| 4 | 2024-03-05 | 2024-03-05 | View Filing |
| 4 | 2024-03-05 | 2024-03-05 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Williams PercentR Strategy | 116.40% | 0.99 | 451 | 0.06 | 0.21 | 29.75 |
| Larry Williams PercentR Strategy | 107.85% | 0.99 | 278 | 0.05 | 0.14 | 21.21 |
| Donchian Channel Strategy | 99.58% | 1.02 | 119 | 0.03 | 0.13 | 12.93 |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxxx | xxxx | xxxx | x |
| xxxxxxxxxx | xxxxxxx% | x | xxxx | xxxx | xxxx | xxxxx |
| xxxxxxxxx | xxxxxxx% | x | xxxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxxx | xxxx | xxxx | xxx |
| xxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxx | xxxxxxx% | x | xxxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxx | xxxxxxx% | x | xxxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxx% | x | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxxx | xxxx | xxxx | xxxxx |
| xxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxx | xxxxx% | xxxx | x | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxx | xxxxxxx% | x | xxxx | x | xxxx | xxxxx |
| xxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | x | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | x | xxxx | xxxxx |
| xxx | xxxxxxx% | x | xxx | x | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | x | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | x | xxxx | xxxxx |
| xxxxxxxxxxxxxxx | xxxxxx% | xxxx | xxx | x | xxxx | xxxxx |
| xxxx | xxxxxxx% | x | xxxx | x | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | x | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | x | xxxxx |
| xxxxxxxxxxxx | xxxxxxxx% | x | xxx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | x | xxxxx | xxxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxxx | xxxxx | xxxxx | xxxxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxxx |
| xxxx | xxxxxxxx% | x | xxxx | xxxxx | xxxxx | xxxxxx |